NBY effective against Monkeypox ! 20X Upside Analyst Rating!!!

NovaBay Pharmaceuticals, Inc. (NBY) owns Avenova, which is EPA listed as an effective disinfectant for monkeypox.

On 5/20/2022 Ascendiant Capital Markets brokerage set a price target of $4.00 for NovaBay Pharmaceuticals, Inc. (NBY).
The stock is now only 0.20usd.

Before the pandemic news, on their last earnings, they mentioned that Avenova Spray unit sales increased 15% with record-high units sold through the OTC channel.

NovaBay CEO: "we expect the majority of 2022 topline growth to come in the second half of this year."

The stock had only insider buys recently, the average being $0.45.
Only 10.976Mil MARKET CAP
The falling wedge in the chart is a bullish sign.

I think we can expect at least a reversal to the $0.64 resistance.

Looking forward to read your opinion about it.
analystforecastsavenovaFundamental AnalysisTechnical IndicatorsmonkeymonkeypoxmonkeypoxstocksmonkeypoxvaccineNBYnovabayPOXTrend Analysis

גם על:

כתב ויתור